Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study of Pegylated Liposomal Doxorubicin, Cyclophosphamide Versus Epirubicin-Cyclophosphamide as Adjuvant Chemotherapy in Her2-negative Stage I and II Breast Cancer Patients

NCT01210768 is registered in ClinicalTrials.gov with TTY Biopharm as lead sponsor.

NCT NCT01210768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01210768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study of Pegylated Liposomal Doxorubicin, Cyclophosphamide Versus Epirubicin-Cyclophosphamide as Adjuvant Chemotherapy in Her2-negative Stage I and II Breast Cancer Patients
Lead sponsor
TTY Biopharm
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2010
Completion date
October 31, 2022
Enrollment
254 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer